Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib vs Dupilumab in Chronic Spontaneous Urticaria
NCT06868212Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Jul 2025; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06868212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868212.